Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment

Pandey, Sanjay; Sharma, Soumya

doi:10.1016/j.jns.2016.11.053

Cited by 90 publications

(115 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some pathological data have shown basal ganglia Lewy body deposits. It can also be associated with other movement disorders, such as essential tremor or parkinsonism [17,18].…”

Section: Meige Syndromementioning

confidence: 99%

Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins

Hassell

Charles

2020

Toxins

View full text Add to dashboard Cite

Blepharospasm and oromandibular dystonia are focal dystonias characterized by involuntary and often patterned, repetitive muscle contractions. There is a long history of medical and surgical therapies, with the current first-line therapy, botulinum neurotoxin (BoNT), becoming standard of care in 1989. This comprehensive review utilized MEDLINE and PubMed and provides an overview of the history of these focal dystonias, BoNT, and the use of toxin to treat them. We present the levels of clinical evidence for each toxin for both, focal dystonias and offer guidance for muscle and site selection as well as dosing.

show abstract

“…Some pathological data have shown basal ganglia Lewy body deposits. It can also be associated with other movement disorders, such as essential tremor or parkinsonism [17,18].…”

Section: Meige Syndromementioning

confidence: 99%

Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins

Hassell

Charles

2020

Toxins

View full text Add to dashboard Cite

show abstract

“…Oromandibular dystonia is known to be associated with dystonia of the neck muscles/spasmodic torticollis, eyelids, and larynx [3], with the combination of upper and lower dystonia sometimes termed cranial-cervical dystonia. When oromandibular dystonia occurs with blepharospasm, it may be referred to as Meige syndrome [4]. Despite the motor definition of primary dystonia, previous studies of dystonia patients have detected widespread abnormalities [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Clinical evaluation of non-motor symptoms in jaw closing dystonia

Narita

Ishii

Kamiya

et al. 2019

Preprint

View full text Add to dashboard Cite

Background The features of non-motor symptoms such as cognitive ability, psychiatric state, and quality of life (QOL) is unknown in patients with jaw closing dystonia. Methods Seven patients with jaw closing dystonia (2 males, 5 females; mean age 60.4 years) and 7 healthy age-and gender-matched subjects (mean age 54.1 years) participated in this study. The patients were examined to determine the location of pain and movement difficulties, with awareness of those measured using a numerical rating scale (0-10).

show abstract

“…[4][5][6] In some cases, OMD may occur concomitantly with dystonia of other areas, as in the case of Meige syndrome, which consists of dystonia of the ocular and facial muscles. 2,7,8 OMD is more common among women, with incidence estimates around 6.9 per 100,000 persons in the United States. 5 The pathophysiology of OMD is unknown, but OMD may be caused by dysfunction in the basal ganglia, hyperactivity of motor nerves related to signaling pathways, reduced spinal cord and brainstem inhibition, aberrant dopamine signaling, or reduced neuroplasticity, with the presence of OMD being correlated with a larger putamen and mosaic nerve loss.…”

Section: Introductionmentioning

confidence: 99%

“…Anticholinergics, including benztropine mesylate, currently boast the highest reported success rate. 1,3,5,6,8,10,11,18,19 The use of botulinum toxin (BTX) injections is well established in the treatment of laryngeal and cervical dystonia and has also been studied in OMD, where most commonly botulinum toxin type A (Botox, Allergan Phar-maceuticals Ireland, Dublin, Ireland) is used. 20 BTX injection is hypothesized to influence the pathophysiology of dystonia and currently represents the first line of treatment for OMD.…”

Section: Introductionmentioning

confidence: 99%

“…20 BTX injection is hypothesized to influence the pathophysiology of dystonia and currently represents the first line of treatment for OMD. 8,20,21 Injections into the affected muscle may be guided by electromyography or ultrasonography. Benefits to injection peak, on average, after 4 weeks, with injections often repeated at 4-month intervals.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The American Academy of Oral Medicine Clinical Practice Statement: Oromandibular dystonia

Stoopler

2018

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

that oromandibular dystonia (also referred to as orofacial dystonia) is a movement disorder causing paroxysmal or sustained contraction of the affected facial muscles. Oromandibular dystonia may occur alone or as a part of a segmental or generalized dystonia and may be idiopathic or secondary to previous medication or drug use, trauma, or neurodegenerative disease. The AAOM also affirms that patients with suspected oromandibular dystonia should be referred to the appropriate oral and/or medical health care provider(s) for comprehensive evaluation and management of the condition. Management of oromandibular dystonia may include conservative therapies, medications, botulinum toxin injections, or peripheral or central surgical approaches. This Clinical Practice Statement was developed as an educational tool on the basis of expert consensus of the American Academy of Oral Medicine (AAOM) leadership. Readers are encouraged to consider the recommendations in the context of their specific clinical situation and to consult, when appropriate, other sources of clinical, scientific, or regulatory information before making a treatment decision.

show abstract

Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment

Cited by 90 publications

References 95 publications

Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins

Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins

Clinical evaluation of non-motor symptoms in jaw closing dystonia

The American Academy of Oral Medicine Clinical Practice Statement: Oromandibular dystonia

Contact Info

Product

Resources

About